We don't know whether the most recent response to this request contains information or not – if you are Dayang Asyiqin please sign in and let everyone know.

UAEM - Licensing and patenting practices of UK research institutions

We're waiting for Dayang Asyiqin to read a recent response and update the status.

Dear University of Dundee,

We previously sent an FOI request asking for information about the licensing practices of your university. This was concerning the time period 18th October 2018 to 18th October 2019. We are now looking to update the information for the following year, 19th October 2019 to 19th October 2020.

The updated request is listed below:
For the purpose of clarity, please adhere to the following definitions when answering these questions:

Definitions
Low and middle income country: A country that is defined as ‘low’, ‘lower-middle’ and ‘upper-middle’ income by the World Bank for the year 2018. Income status defined by GNI per capita.
Source: World bank, available online [https://tinyurl.com/y5dwc2qv]
A patent grants an inventor the exclusive rights to his or her invention. A patent holder can stop other people from selling, manufacturing, producing, or using the invention for a certain period of time.
Source: Upcouncil, available online [https://www.upcounsel.com/what-is-a-pate...
Licence: Permission for the licensee to use the intellectual property rights
Source: TaylorWessing, available online [https://www.taylorwessing.com/download/a...
Exclusive Licence: A licence that allows only the named licensee to exploit the relevant IP rights, the licensor is also excluded from exploiting these IP rights.
Non-Exclusive Licence: A licence that grants any number of licensees to exploit the IP.
Source: TaylorWessing, available online [https://www.taylorwessing.com/synapse/co...
Health Technology: ‘Health technology as defined by the WHO: “A health technology is the application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures and systems developed to solve a health problem and improve quality of lives.’
Source: WHO, available online [https://www.who.int/health-technology-as...
START FOI request:
Q1. Has the university committed to licensing its medical discoveries in ways that promote access and affordability in Low- and Middle- Income Countries? If yes, please provide a link or PDF to the relevant policy document.
Q2. Please provide an Excel spreadsheet with headings as displayed below with all the health technologies LICENSED by the university in the period 19th October 2019 to 19th October 2020 AND specify which countries they were licensed in AND specify whether they are exclusive or non-exclusive licenses.
Health Technology Licensed | Country of Licensing | Type of License (Exclusive or Non-Exclusive)
Q3. Please provide a list of patents granted to your organization in the period 19th October 2019 to 19th October 2020, listed by patent family, indicating countries/regions in which the patent has been granted.

Q4. In the period 19th October 2019 to 19th October 2020, has the university shared its best practices for promoting access to medicines through non-exclusive licensing by carrying out any of the following activities?

❏ Contributed sample clauses to the AUTM Global Health Toolkit
❏ Published an article, guidance, or other literature on access licensing practices
❏ Formally presented on access licensing practices at an academic or professional event, or at another university
❏ Informally shared or discussed access licensing practices with administrators at other universities
❏ Other
❏ None
(Tick as appropriate)

Q5. What actions has the technology transfer office (TTO) undertaken in the period 19th October 2019 to 19th October 2020 to improve access to the technologies they license in low-and middle-income settings?
END FOI request.

If you have any questions please do not hesitate to contact me by email.
Yours faithfully,
Dayang Asyiqin

FreedomOfInformation, University of Dundee

Thank you for your email. If your message contains a request for
information the University will respond no later than 20 working days from
its receipt (or one month from receipt in the case of requests for your
own personal information).

Kind regards,

Dr Richard Parsons

Director LLC & CI

University of Dundee

Dundee DD1 4HN

The University of Dundee is a registered Scottish Charity, No: SC015096

FreedomOfInformation, University of Dundee

1 Attachment

Dear Dayang
Thank you for your email and request for information. I am very sorry for
the delay in replying. Colleagues have provided the information attached
and below. Please let me know if you have any other questions. 
Apologies again for the delay, 
Kind regards
Caroline Brown
FOI Team

 

 

Q1. Has the university committed to licensing its medical discoveries in
ways that promote access and affordability in Low- and Middle- Income
Countries? If yes, please provide a link or PDF to the relevant policy
document.

 

A1.

All Drug Discovery Unit programmes undertaken at University of Dundee that
seek to address diseases of low and middle income countries are carried
out by us and our partners on a not-for-profit basis. Our obligations to
our funders are covered in our individual funding and collaboration
agreements, which we are unable to share.

Resulting candidate drugs are licenced to organisations to carry out
preclinical and clinical development, and supplying drugs once registered
that work to the same model, with the caveat the eventual manufacturer of
a drug can make a small appropriate profit as an incentive to make the
drug.  Our policy is to only patent candidate drugs that will enter
preclinical develop to comply with the requirements of our funders and to
ensure freedom to operate for organisations carrying out preclinical and
clinical development, and supplying drugs once registered.

 

Q2. Please provide an Excel spreadsheet with headings as displayed below
with all the health technologies LICENSED by the university in the past
year AND specify which countries they were licensed in AND specify whether
they are exclusive or non-exclusive licenses.

Health Technology Licensed | Country of Licensing | Type of License
(Exclusive or Non-Exclusive)

 

A2. We are unable to provide this information as it is commercial in
confidence (s 33 1(b) FOISA)

 

Q3. Please provide a list of patents granted to your organization in the
period 18th October 2018 and 18th October 2019, listed by patent family,
indicating countries/regions in which the patent has been granted.

 

A3. Please see attached a list of patents granted to our organization in
the period 18 October 2019 to 18 October 2020

 

Q4.Has the university shared its best practices for promoting access to
medicines through non-exclusive licensing by carrying out any of the
following activities?

 

❏ Contributed sample clauses to the AUTM Global Health Toolkit ❏ Published
an article, guidance, or other literature on access licensing
practices ❏√  Formally presented on access licensing practices at an
academic or professional event, or at another university ❏ Informally
shared or discussed access licensing practices with administrators at
other universities ❏ Other  

 

Q5. What actions has the technology transfer office (TTO) undertaken in
the past year to improve access to the technologies they license in low-
and middle-income settings? 

 

A5. The University is committed to licensing its medical technologies for
patient benefit globally. The Drug Discovery Unit has focused on the
delivery of new drugs for diseases that particularly affect LMIC since it
was established in 2006.

The University of Dundee is a registered Scottish Charity, No: SC015096

We don't know whether the most recent response to this request contains information or not – if you are Dayang Asyiqin please sign in and let everyone know.